ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2470

Does Structural Progression of Knee Osteoarthritis Measured with Magnetic Resonance Imaging or Radiography Predict Knee Replacement? – Data From the Osteoarthritis Initiative

Felix Eckstein1, C. Kent Kwoh2, Robert M. Boudreau3, Zhijie Wang4, Michael J. Hannon4, Wolfgang Wirth1, Ali Guermazi5, Frank Roemer6, Michael C. Nevitt7, Markus R. John8, Leena Sharma9, Jeffrey W. Duryea10, David J. Hunter11 and Osteoarthritis Initiative Investigators12, 1Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, 2School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Epidemiology, University of Pittsburgh, Pittsburgh, PA, 4Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Radiology, Boston University, Boston, MA, 6Klinikum Augsburg, Augsburg, Germany, 7Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, 8Novartis Pharma AG, Basel, Switzerland, 9Northwestern University, Chicago, IL, 10Dept of Radiology, Brigham & Women, Boston, MA, 11Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 12San Francisco

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, Knee, Magnetic resonance imaging (MRI), osteoarthritis and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments

Session Type: Abstract Submissions (ACR)

Background/Purpose: Imaging biomarkers that predict relevant clinical endpoints, such as knee replacement (KR), are valuable tools for knee osteoarthritis prognosis. Currently, measurement of minimum radiographic joint space width (mJSW) is the accepted standard for testing the efficacy of disease modifying drugs (DMOADs) in clinical trials. The purpose of this study was to compare the predictive power of magnetic resonance imaging (MRI)-based longitudinal measures of cartilage loss and mJSW for KR.

Methods: We studied knees from Osteoarthritis Initiative (OAI) participants who received a KR between 24 and 60 month (M) follow-up (confirmed by radiography and/or review of hospital records). A matched control knee that did not receive a KR during this period was selected for each case, with the same sex, similar age (within 5 years), and the same baseline Kellgren Lawrence (KL) grade (central X-ray readings; strata 0-1, 2, 3, 4). Knees were not discordant for medial vs. lateral semi-quantitative joint space narrowing (JSN). Medial femorotibial compartment (MFTC) cartilage thickness change was determined from a sagittal 3 Tesla double echo steady state water excitation (DESSwe) MRI sequence, and, mJSW from fixed flexion radiography. The time points prior to KR (T0) and that 12 months earlier (T-1) were analyzed in case knees (i.e. in a knee with KR between 24M and 36M: 24M=T0;12M=T-1), and the same time points in control knees, with blinding to acquisition order. P-values for differences in longitudinal change between case/control pairs were assessed using the Wilcoxon signed rank test, and the area (AUC) under the receiver operation curve (ROC)

Results: 261 knees of 225 OAI participants received a KR (between 24M and 60M). Of these, 93 had central X-ray readings, JSW, and MRI readings available at both T0 and T-1, and a matched control based on the above criteria (38 men, 55 women, age 63.4±9.3, BMI 30.2±4.9). Medial (MFTC) cartilage loss (over a 12 month period prior to KR), measured with MRI, was significantly greater in KR case than in control knees (-0.13±0.29 vs. -0.04±0.15mm; p=0.038, AUC=0.57). The differences in longitudinal change was borderline significant for the central MFTC (-0.24±0.57 vs. -0.07±0.23 mm; p=0.079, AUC=0.57) and was not significant for the change in radiographic mJSW (-0.19±0.91 vs. 0.01±0.58mm; p=0.397, AUC=0.55). The difference in cartilage loss (MRI) between KR case and control knees was particularly strong in knees with early radiographic OA (KLG2: n=22; MFTC p=0.008; AUC=0.72), whereas no difference in mJSW change was detectable in KLG2 case/control pairs (p=0.126; AUC=0.58).

Conclusion: Medial compartment longitudinal cartilage thickness loss, measured with MRI, predicts knee replacement as a clinical endpoint. In contrast, no significant difference in the 12 month change of radiographic mJSW was detected between case and control knees in the above sample. Given the relationship with an important clinical endpoint (i.e. knee replacement), MRI-based measures of cartilage thickness change are useful imaging biomarkers for clinical trials, for instance to demonstrate the efficacy of a DMOAD. The current findings also support the concept that treatments that slow cartilage loss may delay or prevent KR.


Disclosure:

F. Eckstein,

Chondrometrics GmbH,

3,

Chondrometrics GmbH,

4,

Novartis AG,

2,

Novartis, MerckSeronoSanofi Aventis, Abbot, Perceptive, Bioclinica,

5;

C. K. Kwoh,
None;

R. M. Boudreau,
None;

Z. Wang,
None;

M. J. Hannon,
None;

W. Wirth,

Chondrometrics GmbH,

3,

Chondrometrics GmbH,

4,

MerckSerono,

5;

A. Guermazi,

BICL, LLC,

4,

AstraZeneca, Genzyme, Novartis, and MerckSerono,

5;

F. Roemer,

Boston Imaging Core Lab,

1,

National Institute of Health,

5,

Merck Serono,

5;

M. C. Nevitt,
None;

M. R. John,

Novartis Pharma AG,

1,

Novartis Pharma AG,

3;

L. Sharma,
None;

J. W. Duryea,
None;

D. J. Hunter,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-structural-progression-of-knee-osteoarthritis-measured-with-magnetic-resonance-imaging-or-radiography-predict-knee-replacement-data-from-the-osteoarthritis-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology